Difficulty: Medium
Average Score: 85%
Practice
Which of the following agents is the most helpful in counteracting the behavioral complications of levodopa?
Correct answer
B
Rationale
In the context of pharmacology and lifespan considerations, the correct answer to the question is B) Clozapine. Clozapine is an atypical antipsychotic that is most helpful in counteracting the behavioral complications of levodopa therapy, such as hallucinations and psychosis, commonly seen in patients with Parkinson's disease.
Carbidopa (option C) is incorrect because it is a peripheral dopa decarboxylase inhibitor used in combination with levodopa to prevent its peripheral conversion to dopamine and reduce side effects like nausea and vomiting, but it does not directly address the behavioral complications.
Tolcapone (option A) is a catechol-O-methyltransferase (COMT) inhibitor used to prolong the effects of levodopa by inhibiting its metabolism. While it can enhance the efficacy of levodopa, it does not specifically target the behavioral complications associated with levodopa therapy.
Pergolide (option D) is a dopamine agonist used in the treatment of Parkinson's disease but is not primarily indicated for counteracting the behavioral complications of levodopa therapy.
Educationally, understanding the appropriate pharmacological interventions for managing the side effects and complications of levodopa therapy is crucial for healthcare professionals working with patients with Parkinson's disease. Clozapine's unique pharmacological profile as an atypical antipsychotic makes it particularly effective in addressing the behavioral issues that can arise with levodopa treatment, highlighting the importance of considering individual patient needs and tailoring treatment plans accordingly.
Carbidopa (option C) is incorrect because it is a peripheral dopa decarboxylase inhibitor used in combination with levodopa to prevent its peripheral conversion to dopamine and reduce side effects like nausea and vomiting, but it does not directly address the behavioral complications.
Tolcapone (option A) is a catechol-O-methyltransferase (COMT) inhibitor used to prolong the effects of levodopa by inhibiting its metabolism. While it can enhance the efficacy of levodopa, it does not specifically target the behavioral complications associated with levodopa therapy.
Pergolide (option D) is a dopamine agonist used in the treatment of Parkinson's disease but is not primarily indicated for counteracting the behavioral complications of levodopa therapy.
Educationally, understanding the appropriate pharmacological interventions for managing the side effects and complications of levodopa therapy is crucial for healthcare professionals working with patients with Parkinson's disease. Clozapine's unique pharmacological profile as an atypical antipsychotic makes it particularly effective in addressing the behavioral issues that can arise with levodopa treatment, highlighting the importance of considering individual patient needs and tailoring treatment plans accordingly.